Literature DB >> 24910948

Relevance of neuronal and glial NPC1 for synaptic input to cerebellar Purkinje cells.

Isabelle Buard1, Frank W Pfrieger2.   

Abstract

Niemann-Pick type C disease is a rare and ultimately fatal lysosomal storage disorder with variable neurologic symptoms. The disease-causing mutations concern NPC1 or NPC2, whose dysfunction entails accumulation of cholesterol in the endosomal-lysosomal system and the selective death of specific neurons, namely cerebellar Purkinje cells. Here, we investigated whether neurodegeneration is preceded by an imbalance of synaptic input to Purkinje cells and whether neuronal or glial absence of NPC1 has different impacts on synapses. To this end, we prepared primary cerebellar cultures from wildtype or NPC1-deficient mice that are glia-free and highly enriched with Purkinje cells. We report that lack of NPC1 in either neurons or glial cells did not affect the excitability of Purkinje cells, the formation of dendrites or their excitatory synaptic activity. However, simultaneous absence of NPC1 from neuronal and glial cells impaired the presynaptic input to Purkinje cells suggesting a cooperative effect of neuronal and glial NPC1 on synapses.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Cerebellum; Inborn error metabolism; Lysosomal storage disease; Neurodegenerative diseases; Neuroglia; Synaptogenesis

Mesh:

Substances:

Year:  2014        PMID: 24910948     DOI: 10.1016/j.mcn.2014.06.003

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  9 in total

Review 1.  Psychiatric and Cognitive Symptoms Associated with Niemann-Pick Type C Disease: Neurobiology and Management.

Authors:  Thomas Rego; Sarah Farrand; Anita M Y Goh; Dhamidhu Eratne; Wendy Kelso; Simone Mangelsdorf; Dennis Velakoulis; Mark Walterfang
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

2.  AAV9-NPC1 significantly ameliorates Purkinje cell death and behavioral abnormalities in mouse NPC disease.

Authors:  Chang Xie; Xue-Min Gong; Jie Luo; Bo-Liang Li; Bao-Liang Song
Journal:  J Lipid Res       Date:  2017-01-04       Impact factor: 5.922

3.  Ontogenesis and Modulation of Intestinal Unesterified Cholesterol Sequestration in a Mouse Model of Niemann-Pick C1 Disease.

Authors:  Adam M Lopez; Charina M Ramirez; Anna M Taylor; Ryan D Jones; Joyce J Repa; Stephen D Turley
Journal:  Dig Dis Sci       Date:  2019-07-17       Impact factor: 3.199

Review 4.  The Cerebellum in Niemann-Pick C1 Disease: Mouse Versus Man.

Authors:  Maria Teresa Fiorenza; Piergiorgio La Rosa; Sonia Canterini; Robert P Erickson
Journal:  Cerebellum       Date:  2022-01-18       Impact factor: 3.648

5.  Impact of Reduced Cerebellar EAAT Expression on Purkinje Cell Firing Pattern of NPC1-deficient Mice.

Authors:  Michael Rabenstein; Franziska Peter; Arndt Rolfs; Moritz J Frech
Journal:  Sci Rep       Date:  2018-02-20       Impact factor: 4.379

6.  NPC1 enables cholesterol mobilization during long-term potentiation that can be restored in Niemann-Pick disease type C by CYP46A1 activation.

Authors:  Daniel N Mitroi; Guadalupe Pereyra-Gómez; Beatriz Soto-Huelin; Fernando Senovilla; Toshihide Kobayashi; Jose A Esteban; María Dolores Ledesma
Journal:  EMBO Rep       Date:  2019-09-18       Impact factor: 8.807

Review 7.  Understanding and Treating Niemann-Pick Type C Disease: Models Matter.

Authors:  Valentina Pallottini; Frank W Pfrieger
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

Review 8.  Lipid Dyshomeostasis and Inherited Cerebellar Ataxia.

Authors:  Jin Zhao; Huan Zhang; Xueyu Fan; Xue Yu; Jisen Huai
Journal:  Mol Neurobiol       Date:  2022-04-14       Impact factor: 5.682

9.  Developmental delay in motor skill acquisition in Niemann-Pick C1 mice reveals abnormal cerebellar morphogenesis.

Authors:  Paola Caporali; Francesco Bruno; Giampiero Palladino; Jessica Dragotto; Laura Petrosini; Franco Mangia; Robert P Erickson; Sonia Canterini; Maria Teresa Fiorenza
Journal:  Acta Neuropathol Commun       Date:  2016-09-01       Impact factor: 7.801

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.